Australian public preferences for the provision of medicinal cannabis: A discrete choice experiment
Pharmacoeconomics and Policy · 2025
DOI: 10.1016/j.pharp.2025.06.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoeconomics and Policy, 2025. Verfasst von Katrina Gething und 3 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Other than measuring public opinion, policy makers have not pursued the involvement of the Australian public in decisions about the provision of medicinal cannabis (MC). This research measures public preferences for the provision of MC and the relationship of these preferences to current Australian policy. A total of 1166 Australian adults completed an online discrete choice experiment (DCE). The DCE consisted of 12 pairwise forced choice policy profiles per participant. Profile alternatives were described according to the attributes access, evidence, medical supervision, intoxicating ingredient, therapy format and cost, and were patient specific. Conditional logit (CL) and latent class analyses were conducted. Participants preferred MC to be prescribed at any time during a patient’s treatment plan and for costs to be subsidised. Oral formulations were preferred to raw flower forms. In general, the public preferred patients to be prescribed MC with low levels of tetrahydrocannabinol (THC). THC levels in MC were not important to the choices of males or when prescribing MC to patients with a terminal condition. Three response groups were found. Group 1 (34.9%) preferred patients to be prescribed oral formulations of low-intoxicating MC when all other medications have failed and there is good evidence for its use. Group 2 (40.3%) preferred MC to be available at any time of a patient’s treatment plan, and medical supervision or the level of intoxicating ingredient in the therapy was not important. Group 3 (24.8%) were the only group to have no preferences for the subsidisation of MC costs. All groups were disinclined toward the prescription of raw cannabis flower. In general, public preferences do not completely align with current Australian policy. The public would likely support the Australian government’s liberal policy on MC for terminal patients. • Cost subsidies were the most important contributor to policy decisions. • The public prefers MC to be available to patients at any time. • There is a preference for MC to be prescribed. • The public prefers patients to use oral formulations of MC. • The public prefers evidence for MC provision
Förderung
- National Health and Medical Research Council
Zitieren
APA
Gething, K., Scuffham, P., Norman, R., & Erku, D. (2025). Australian public preferences for the provision of medicinal cannabis: A discrete choice experiment. Pharmacoeconomics and Policy. https://doi.org/10.1016/j.pharp.2025.06.002
Vancouver
Gething K, Scuffham P, Norman R, Erku D. Australian public preferences for the provision of medicinal cannabis: A discrete choice experiment. Pharmacoeconomics and Policy. 2025. doi:10.1016/j.pharp.2025.06.002
BibTeX
@article{Gething2025,
author = {Gething, Katrina and Scuffham, Paul and Norman, Richard and Erku, Daniel},
title = {Australian public preferences for the provision of medicinal cannabis: A discrete choice experiment},
journal = {Pharmacoeconomics and Policy},
year = {2025},
doi = {10.1016/j.pharp.2025.06.002}
}
EUVIMED